Countdown to the New Year – 2023 Edition

This year, C3 collaborated with 5 other LGMD organizations to publish the Voice of the Patient Report, summarizing the 2022 Externally-Led Patient Focused Drug Development Meeting and highlighting the unmet medical needs of the LGMD community. READ MORE

Connected with over 40 members of the LGMD2A/R1 community at the International LGMD Conference in Washington, DC. SEE PHOTOS

Launched the patient-powered LGMD2A/Calpainopathy Registry for individuals with CAPN3 mutations. JOIN NOW

Awarded 2 research grants to improve genetic diagnosis and outcome measure development for LGMD2A/R1.

Learn about genetic diagnosis and outcome measure development.

Committed to 1 singular focus: to drive research towards a cure for LGMD2A/R1. Donate to make a year-end contribution to advance treatments for families impacted by LGMD2A/R1.